Not in San Diego: We took a close look at the potential for targeting gamma delta (š¯˛¬š¯¯³) T cells early last year in an extended mini-series looking at the landscape including some of the early companies leading the way in this niche.

Since then thereā€™s been a raft of company related announcements and collaborations in recent months, highlighting the ongoing interest in this field.

In this post, itā€™s time to revisit the original landscape (link), as well as explore how well some of the biotech companies who are active in this space are navigating the R&D roller coaster.

We will also be discussing recent data presented at the AACR20 virtual meetings.

So what did we learn about gamma delta T Cell therapies at AACR20 – who stands out from the increasingly crowded pack?

To learn more from our oncology analysis and get a heads up on insights and commentary emerging from the AACR meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by